A randomized, prospective, comparative study to evaluate the efficacy and safety of diced ADM alone use versus combined use of diced ADM and micronized ADM filler for reconstruction of defect areas after breast conserving surgery in breast cancer patients

Start Date31 May 2023

Sponsor / Collaborator

Kosin University Gospel Hospital

NCT06075160 / RecruitingNot Applicable

Prospective Evaluation of Long-term Clinical Outcomes After Resting Full-cycle Ratio (RFR)-Guided Percutaneous Coronary Revascularization; A Multi-center, International, Single Arm Interventional, Comparing Registry (COMFORT Study)

The purpose of this study is to compare the clinical outcomes of a 2-year follow-up to determine whether RFR-guided coronary intervention is non-inferior to FFR-guided coronary intervention in patients with intermediate coronary stenosis.

Start Date27 Jul 2022

Sponsor / Collaborator

Pusan National University Hospital

[+9]

KCT0007600 / RecruitingNot ApplicableIIT

Factors associated with improved aesthetic outcomes in prepectoral direct-to-implant breast reconstruction

Start Date22 Jul 2022

Sponsor / Collaborator

Kosin University Gospel Hospital

100 Clinical Results associated with Kosin University Gospel Hospital

0 Patents (Medical) associated with Kosin University Gospel Hospital

863

Literatures (Medical) associated with Kosin University Gospel Hospital

01 Sep 2024·The Lancet

Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea

Article

Author: Hong, Soon Jun ; Kim, Sang Min ; Kim, Jung-Sun ; Lee, Jun-Won ; Cho, Deok-Kyu ; Choe, Jeong Cheon ; Lee, Jung-Hee ; Ahn, Jong-Hwa ; Hong, Myeong-Ki ; Kim, Soo-Joong ; Lee, Sang-Hyup ; Lee, Seung-Jun ; Hong, Sung-Jin ; Ko, Young-Guk ; Heo, Jung Ho ; Kim, Byeong-Keuk ; Lee, Jong-Young ; Lee, Jin Bae ; Kim, Jin Won ; Lee, Yong-Joon ; Kim, Dong-Kie ; Won, Hoyoun ; Hur, Seung-Ho ; Jang, Yangsoo ; Jang, Ji-Yong ; Hong, Young Joon ; Ahn, Chul-Min ; Choi, Donghoon ; Koh, Jin Sin ; Yang, Tae-Hyun

BACKGROUNDDespite the detailed imaging information provided by optical coherence tomography (OCT) during percutaneous coronary intervention (PCI), clinical benefits of this imaging technique in this setting remain uncertain. The aim of the OCCUPI trial was to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, assessed as the rate of major adverse cardiac events at 1 year.METHODSThis investigator-initiated, multicentre, randomised, open-label, superiority trial conducted at 20 hospitals in South Korea enrolled patients aged 19-85 years for whom PCI with drug-eluting stents was clinically indicated. After diagnostic angiography, clinical and angiographic findings were assessed to identify patients who met the criterion of having one or more complex lesions. Patients were randomly assigned 1:1 to receive PCI with OCT guidance (OCT-guidance group) or angiography guidance without OCT (angiography-guidance group). Web-response permuted-block randomisation (mixed blocks of four or six) was used at each participating site to allocate patients. The allocation sequence was computer-generated by an external programmer who was not involved in the rest of the trial. Outcome assessors were masked to group assignment. Patients, follow-up health-care providers, and data analysers were not masked. PCI was done according to conventional standard methods with everolimus-eluting stents. The primary endpoint was major adverse cardiac events (a composite of cardiac death, myocardial infarction, stent thrombosis, or ischaemia-driven target-vessel revascularisation), 1 year after PCI. The primary analysis was done in the intention-to-treat population. The margin used to establish superiority was 1·0 as a hazard ratio. This trial is registered with ClinicalTrials.gov (NCT03625908) and is completed.FINDINGSBetween Jan 9, 2019, and Sept 22, 2022, 1604 patients requiring PCI with drug-eluting stents for complex lesions were randomly assigned to receive either OCT-guided PCI (n=803) or angiography-guided PCI (n=801). 1290 (80%) of 1604 patients were male and 314 (20%) were female. The median age of patients at randomisation was 64 years (IQR 57-70). 1588 (99%) patients completed 1-year follow-up. The primary endpoint occurred in 37 (5%) of 803 patients in the OCT-guided PCI group and 59 (7%) of 801 patients in the angiography-guided PCI group (absolute difference -2·8% [95% CI -5·1 to -0·4]; hazard ratio 0·62 [95% CI 0·41 to 0·93]; p=0·023). Rates of stroke, bleeding events, and contrast-induced nephropathy were not significantly different across the two groups.INTERPRETATIONAmong patients who required drug-eluting stent implantation for complex lesions, OCT guidance resulted in a lower incidence of major adverse cardiac events at 1 year compared with angiography guidance. These findings indicate the existence of a therapeutic benefit of OCT as an intravascular imaging technique for PCI guidance in patients with complex coronary lesions.FUNDINGAbbott Vascular and Cardiovascular Research Center.TRANSLATIONFor the Korean translation of the abstract see Supplementary Materials section.

01 Sep 2024·Journal of Clinical Oncology

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Article

Author: Park, ChoHyun ; Kim, Hyunki ; Sul, Ji Young ; Oh, Sang Cheul ; Noh, Sung Hoon ; Kim, In-Ho ; Cheong, Jae-Ho ; Ryoo, Baek-Yeol ; Kim, Hyung-Don ; Yook, Jeong Hwan ; Kim, Jong Gwang ; Lee, Jong Seok ; Lee, Nam Su ; Park, Young-Kyu ; Kim, Young-Woo ; Lee, Sang Ho ; Zang, Dae Young ; Beom, Seung-Hoon ; Rha, Sun Young ; Jang, You Jin ; Hwang, Jun-Eul ; Kang, Yoon-Koo ; Kim, Hark Kyun ; Kim, Beom Su ; Park, Young Soo ; Kim, Jin Young ; Ryu, Min-Hee ; Jeong, Oh ; Chung, Ik Joo ; Yoo, Chang Hak ; Kang, Seok Yun ; Heo, Mi Hwa ; Kook, Myeong-Cherl ; Yoo, Moon-Won ; Ryu, Seung Wan

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The phase III PRODIGY study demonstrated that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 (DOS) followed by surgery and adjuvant S-1 chemotherapy (CSC) improved progression-free survival (PFS) compared with surgery followed by adjuvant S-1 (SC) for patients with resectable locally advanced gastric cancer (LAGC) with clinical T2-3N+ or T4Nany disease. The primary end point was PFS. Overall survival (OS) was the secondary end point. We herein report the long-term follow-up outcomes, including OS, from this trial. A total of 238 and 246 patients were randomly assigned to the CSC and SC arms, respectively, and were treated (full analysis set). As of the data cutoff (September 2022), the median follow-up duration of the surviving patients was 99.5 months. Compared with SC, CSC significantly increased the OS (adjusted hazard ratio [HR], 0.72; stratified log-rank P = .027) with an 8-year OS rate of 63.0% and 55.1% for the CSC and SC arms, respectively. CSC also significantly improved the PFS (HR, 0.70; stratified log-rank P = .016). In conclusion, neoadjuvant DOS chemotherapy, as part of perioperative chemotherapy, prolonged the OS of Asian patients with LAGC relative to patients treated with surgery and adjuvant S-1. It should be considered one of the standard treatment options for patients with LAGC in Asia.

01 Sep 2024·The Korean Journal of Internal Medicine

Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease

Article

Author: Kim, Bo Young ; Kim, Hyun-Sook ; Kim, Yun Sung ; Lee, Myeung-Su ; Kim, Geun-Tae ; Kim, Sang-Hyon ; Jung, Jae Hyun ; Kim, Sung Soo ; Hur, Jin-Wuk ; Lee, Sang-Il ; Park, Suyeon ; Lee, Kyung-Ann ; Cheon, Yun Hong ; Hong, Seung-Jae

Background/Aims: To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).Methods: This multi-center retrospective study included RA patients receiving abatacept or csDMARDs who underwent at least two pulmonary function tests and/or chest high-resolution computed tomography (HRCT). We compared the following outcomes between the groups: progression of RA-ILD, development of new ILD in RA patients without ILD at baseline, 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR), and safety. Longitudinal changes were compared between the groups by using a generalized estimating equation.Results: The study included 123 patients who were treated with abatacept (n = 59) or csDMARDs (n = 64). Nineteen (32.2%) and 38 (59.4%) patients treated with abatacept and csDMARDs, respectively, presented with RA-ILD at baseline. Newly developed ILD occurred in one patient receiving triple csDMARDs for 32 months. Among patients with RA-ILD at baseline, ILD progressed in 21.1% of cases treated with abatacept and 34.2% of cases treated with csDMARDs during a median 21-month follow-up. Longitudinal changes in forced vital capacity and diffusing capacity for carbon monoxide were comparable between the two groups. However, the abatacept group showed a more significant decrease in DAS28-ESR and glucocorticoid doses than csDMARDs group during the follow-up. The safety of both regimens was comparable.Conclusions: Abatacept and csDMARDs showed comparable effects on the development and stabilization of RA-ILD. Nevertheless, compared to csDMARDs, abatacept demonstrated a significant improvement in disease activity and led to reduced glucocorticoid use.

100 Deals associated with Kosin University Gospel Hospital

100 Translational Medicine associated with Kosin University Gospel Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 18 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Kosin University Gospel Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 18 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing